À l'annexe VI, la partie 3 est modifiée comme suit:
1) le tableau 3.1 est modifié comme suit:
a) l'entrée correspondant au numéro index 015-188-00-X est supprimée;
b) les entrées correspondant aux numéros index 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5, 605-008-00-3 et 616-035-00-5 sont remplacées par les entrées suivantes:
| «006-086-00-6 | fenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate | 276-696-7 | 72490-01-8 |
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H351
H400
H410
|
GHS08
GHS09
Wng
|
H351
H410
| |
M = 1
M = 10 000
|
| 015-154-00-4 | ethephon; 2-chloroethylphosphonic acid | 240-718-3 | 16672-87-0 |
Acute Tox. 3
Acute Tox. 4
Acute Tox. 4
Skin Corr. 1C
Aquatic Chronic 2
|
H311
H332
H302
H314
H411
|
GHS06
GHS05
GHS09
Dgr
|
H311
H332
H302
H314
H411
| EUH071 | |
| 015-192-00-1 | tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate | 432-770-2 | 139189-30-3 | Skin Sens. 1 | H317 |
GHS07
Wng
| H317 | | |
| 601-023-00-4 | ethylbenzene | 202-849-4 | 100-41-4 |
Flam. Liq. 2
Acute Tox. 4*
STOT RE 2
Asp. Tox. 1
|
H225
H332
H373 (organes de l'ouïe)
H304
|
GHS02
GHS07
GHS08
Dgr
|
H225
H332
H373
H304
| | |
| 601-026-00-0 | styrene | 202-851-5 | 100-42-5 |
Flam. Liq. 3
Repr. 2
Acute Tox. 4*
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
|
H226
H361d
H332
H372 (organes de l'ouïe)
H315
H319
|
GHS02
GHS08
GHS07
Dgr
|
H226
H361d
H332
H372
H315
H319
| | * | D
| 603-061-00-7 |
tetrahydro-2-furylmethanol;
tetrahydrofurfuryl alcohol
| 202-625-6 | 97-99-4 |
Repr. 1B
Eye Irrit. 2
|
H360Df
H319
|
GHS08
GHS07
Dgr
|
H360Df
H319
| | |
| 605-001-00-5 | formaldehyde …% | 200-001-8 | 50-00-0 |
Carc. 1B
Muta. 2
Acute Tox. 3*
Acute Tox. 3*
Acute Tox. 3*
Skin Corr. 1B
Skin Sens. 1
|
H350
H341
H301
H311
H331
H314
H317
|
GHS08
GHS06
GHS05
Dgr
|
H350
H341
H301
H311
H331
H314
H317
| |
*
Skin Corr. 1B; H314: C ≥ 25 %
Skin Irrit. 2; H315: 5 % ≤ C < 25 %
Eye Irrit. 2; H319: 5 % ≤ C < 25 %
STOT SE 3; H335: C ≥ 5 %
Skin Sens. 1; H317: C ≥ 0,2 %
| B, D
| 605-008-00-3 |
acrolein;
prop-2-enal;
acrylaldehyde
| 203-453-4 | 107-02-8 |
Flam. Liq. 2
Acute Tox. 1
Acute Tox. 2
Acute Tox. 3
Skin Corr. 1B
Aquatic Acute 1
Aquatic Chronic 1
|
H225
H330
H300
H311
H314
H400
H410
|
GHS02
GHS06
GHS05
GHS09
Dgr
|
H225
H330
H300
H311
H314
H410
| EUH071 |
Skin Corr. 1B;
H314: C ≥ 0,1 %
M = 100
M = 1
| D
| 616-035-00-5 |
cymoxanil (ISO);
2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide
| 261-043-0 | 57966-95-7 |
Repr. 2
Acute Tox. 4
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H361fd
H302
H373 (sang, thymus)
H317
H400
H410
|
GHS08
GHS07
GHS09
Wng
|
H361fd
H302
H373
H317
H410
| |
M = 1
M = 1»
|
c) les entrées ci-après sont insérées conformément à l'ordre des entrées établi au tableau 3.1:
| «050-028-00-2 | 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate | 260-829-0 | 57583-35-4 |
Repr. 2
Acute Tox. 4
STOT RE 1
Skin Sens. 1A
|
H361d
H302
H372 (système nerveux, système immunitaire)
H317
|
GHS08
GHS07
Dgr
|
H361d
H302
H372
H317
| | |
| 050-029-00-8 | dimethyltin dichloride | 212-039-2 | 753-73-1 |
Repr. 2
Acute Tox. 2
Acute Tox. 3
Acute Tox. 3
STOT RE 1
Skin Corr. 1B
|
H361d
H330
H301
H311
H372 (système nerveux, système immunitaire)
H314
|
GHS08
GHS06
GHS05
Dgr
|
H361d
H330
H301
H311
H372
H314
| EUH071 | |
| 601-088-00-9 | 4-vinylcyclohexene | 202-848-9 | 100-40-3 | Carc. 2 | H351 |
GHS08
Wng
| H351 | | |
| 601-089-00-4 | muscalure; cis-tricos-9-ene | 248-505-7 | 27519-02-4 | Skin Sens. 1B | H317 |
GHS07
Wng
| H317 | | |
| 604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 |
Repr. 2
Skin Irrit. 2
Eye Dam. 1
|
H361f
H315
H318
|
GHS08
GHS05
Dgr
|
H361f
H315
H318
| | |
| 604-091-00-3 | etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether | 407-980-2 | 80844-07-1 |
Lact.
Aquatic Acute 1
Aquatic Chronic 1
|
H362
H400
H410
|
GHS09
Wng
|
H362
H410
| |
M = 100
M = 1 000
|
| 606-146-00-7 | tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one | - | 87820-88-0 |
Carc. 2
Acute Tox. 4
Aquatic Chronic 2
|
H351
H302
H411
|
GHS08
GHS07
GHS09
Wng
|
H351
H302
H411
| | |
| 606-147-00-2 | cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one | 405-230-9 | 101205-02-1 | Repr. 2 | H361d |
GHS08
Wng
| H361d | | |
| 607-705-00-8 | benzoic acid | 200-618-2 | 65-85-0 |
STOT RE 1
Skin Irrit. 2
Eye Dam. 1
|
H372 (poumons) (inhalation)
H315
H318
|
GHS08
GHS05
Dgr
|
H372 (poumons) (inhalation)
H315
H318
| | |
| 607-706-00-3 | methyl 2,5-dichlorobenzoate | 220-815-7 | 2905-69-3 |
Acute Tox. 4
STOT SE 3
Aquatic Chronic 2
|
H302
H336
H411
|
GHS07
GHS09
Wng
|
H302
H336
H411
| | |
| 612-287-00-5 | fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine | - | 79622-59-6 |
Repr. 2
Acute Tox. 4
Eye Dam. 1
Skin Sens. 1 A
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H332
H318
H317
H400
H410
|
GHS08
GHS07
GHS05
GHS09
Dgr
|
H361d
H332
H318
H317
H410
| |
M = 10
M = 10
|
| 613-317-00-X | penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole | 266-275-6 | 66246-88-6 |
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H302
H400
H410
|
GHS08
GHS07
GHS09
Wng
|
H361d
H302
H410
| |
M = 1
M = 1
|
| 613-318-00-5 | fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate | - | 473798-59-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | | |
| 616-212-00-7 | 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate | 259-627-5 | 55406-53-6 |
Acute Tox. 3
Acute Tox. 4
STOT RE 1
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H331
H302
H372 (larynx)
H318
H317
H400
H410
|
GHS06
GHS08
GHS05
GHS09
Dgr
|
H331
H302
H372 (larynx)
H318
H317
H410
| |
M = 10
M = 1»
|
2) le tableau 3.2 est modifié comme suit:
a) l'entrée correspondant au numéro index 015-188-00-X est supprimée;
b) les entrées correspondant aux numéros index 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5 et 616-035-00-5 sont remplacées par les entrées correspondantes suivantes:
| «006-086-00-6 | fenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate | 276-696-7 | 72490-01-8 |
Carc. Cat. 3; R40
N; R50-53
|
Xn; N
R: 40-50/53
S: (2-)22-36/37-60-61
|
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
|
| 015-154-00-4 | ethephon; 2-chloroethylphosphonic acid | 240-718-3 | 16672-87-0 |
C; R34
Xn; 20/21/22
N; R51-53
|
C; N
R: 20/21/22-34-51/53
S: (1/2-)26-36/37/39-45-61
| Xi; R37: 5 % ≤ C < 10 % |
| 015-192-00-1 | tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate | 432-770-2 | 139189-30-3 | R43 |
Xi
R: 43
S: (2-)24-37
| |
| 601-023-00-4 | ethylbenzene | 202-849-4 | 100-41-4 |
F; R11
Xn; R20-48/20-65
|
F; Xn
R: 11-20-48/20-65
S: (2-)16-24/25-29-62
| |
| 601-026-00-0 | styrene | 202-851-5 | 100-42-5 |
Repr. Cat. 3; R63
Xn; R20-48/20
Xi; R36/38
R10
|
Xn
R: 10-20-36/38-48/20-63
S: (2-)23-36/37-46
|
Xn; R20: C ≥ 12,5 %
Xi; R36/38: C ≥ 12,5 %
| D
| 603-061-00-7 |
tetrahydro-2-furylmethanol;
tetrahydrofurfuryl alcohol
| 202-625-6 | 97-99-4 |
Repr. Cat. 2; R61
Repr. Cat. 3; R62
Xi; R36
|
T
R: 36-61-62
S: 45-53
| Xi; R36: C ≥ 10 % |
| 605-001-00-5 | formaldehyde …% | 200-001-8 | 50-00-0 |
Carc. Cat. 2; R45
Muta. Cat. 3; R68
T; R23/24/25
C; R34
R43
|
T
R: 23/24/25-34-43-45-68
S: 45-53
|
T; R23/24/25: C ≥ 25 %
Xn; R20/21/22: 5 % ≤ C < 25 %
C; R34: C ≥ 25 %
Xi; R36/37/38: 5 % ≤ C < 25 %
R43: C ≥ 0,2 %
| B, D
| 616-035-00-5 |
cymoxanil (ISO);
2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide
| 261-043-0 | 57966-95-7 |
Repr. Cat. 3; R62-63
Xn; R22-48/22
R43
N; R50-53
|
Xn; N
R: 22-43-48/22-62-63-50/53
S: (2-)36/37-46-60-61
|
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %»
|
c) les entrées ci-après sont insérées conformément à l'ordre des entrées établi au tableau 3.2:
| «050-028-00-2 | 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate | 260-829-0 | 57583-35-4 |
Repr. Cat. 3; R63
T; R48/25
Xn; R22
R43
|
T
R: 22-43-48/25-63
S: (1/2-)36/37-45
| |
| 050-029-00-8 | dimethyltin dichloride | 212-039-2 | 753-73-1 |
Repr. Cat. 3; R63
T+; 26
T; R24/25-48/25
C; R34
|
T+
R: 24/25-26-34-48/25-63
S: (1/2-)26-28-36/37/39-45-63
| |
| 601-088-00-9 | 4-vinylcyclohexene | 202-848-9 | 100-40-3 | Carc. Cat. 3; R40 |
Xn
R: 40
S: (2-)36/37
| |
| 601-089-00-4 | muscalure; cis-tricos-9-ene | 248-505-7 | 27519-02-4 | R43 |
Xi
R: 43
S: (2-)24-37
| |
| 604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 |
Repr. Cat. 3; R62
Xi; R38-41
|
Xn
R: 38-41-62
S: (2-)26-36/37/39-46
| |
| 604-091-00-3 | etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether | 407-980-2 | 80844-07-1 |
R64
N; R50-53
|
N
R: 50/53-64
S: 60-61
|
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
|
| 606-146-00-7 | tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one | – | 87820-88-0 |
Carc. Cat. 3; R40
Xn; R22
N; R51-53
|
Xn; N
R: 22-40-51/53
S: (2-)36/37-60-61
| |
| 606-147-00-2 | cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one | 405-230-9 | 101205-02-1 |
F; R11
Repr. Cat. 3; R63
|
F; Xn
R: 11-63
S: (2-)16-36/37-46
| |
| 607-705-00-8 | benzoic acid | 200-618-2 | 65-85-0 |
T; R48/23
Xi; R38-41
|
T
R: 38-41-48/23
S: (1/2-)26-39-45-63
| |
| 607-706-00-3 | methyl 2,5-dichlorobenzoate | 220-815-7 | 2905-69-3 |
Xn; R22
N; R51-53
|
Xn; N
R: 22-51/53
S: (2-) 46-61
| |
| 612-287-00-5 | fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine | - | 79622-59-6 |
Repr. Cat. 3; R63
Xn; R20
Xi; R41
R43
N; R50-53
|
Xn; N
R: 20-41-43-50/53-63
S: (2-)26-36/37/39-46-60-61
|
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
|
| 613-317-00-X | penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole | 266-275-6 | 66246-88-6 |
Repr. Cat. 3; R63
Xn; R22
N; R50-53
|
Xn; N
R: 22-50/53-63
S: (2-) 36/37-46-60-61
|
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
|
| 613-318-00-5 | fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate | - | 473798-59-3 | N; R51-53 |
N
R: 51/53
S: 60-61
| |
| 616-212-00-7 | 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate | 259-627-5 | 55406-53-6 |
T; R23-48/23
Xn; R22
Xi; R41
R43
N; R50
|
T; N
R: 22-23-41-43-48/23-50
S: (1/2-)24-26-37/39-45-63
| N; R50: C ≥ 2,5 %» |